E
Emmanuel Delaporte
Researcher at university of lille
Publications - 197
Citations - 6155
Emmanuel Delaporte is an academic researcher from university of lille. The author has contributed to research in topics: Rituximab & Crohn's disease. The author has an hindex of 34, co-authored 186 publications receiving 5468 citations. Previous affiliations of Emmanuel Delaporte include Pasteur Institute & Lille University of Science and Technology.
Papers
More filters
Journal ArticleDOI
High-affinity IgE receptor on eosinophils is involved in defence against parasites
Abdelillah Soussi Gounni,Bouchaib Lamkhioued,Kenichi Ochiai,Yoichi Tanaka,Emmanuel Delaporte,André Capron,Jean-Pierre Kinet,Monique Capron +7 more
TL;DR: Results indicate that FcεRI may play a major part in immune defence against parasites and participates in eosinophil-mediated cytotoxicity against S. mansoni.
Journal ArticleDOI
A Comparison of Oral and Topical Corticosteroids in Patients with Bullous Pemphigoid
Pascal Joly,Jean-Claude Roujeau,Jacques Benichou,Catherine Picard,Brigitte Dréno,Emmanuel Delaporte,Loïc Vaillant,Michel D'Incan,Patrice Plantin,Christophe Bedane,Paul J Young,Philippe Bernard +11 more
TL;DR: Topical corticosteroid therapy is effective for both moderate and severe bullous pemphigoid and is superior to oral corticosterone therapy for extensive disease.
Journal ArticleDOI
A Single Cycle of Rituximab for the Treatment of Severe Pemphigus
Pascal Joly,Hugo Mouquet,Jean-Claude Roujeau,Michel D'Incan,Danièle Gilbert,Serge Jacquot,Marie-Lise Gougeon,Christophe Bedane,Ralf Müller,Brigitte Dréno,Marie-Sylvie Doutre,Emmanuel Delaporte,Christine Pauwels,Nathalie Franck,Frédéric Caux,Catherine Picard,E. Tancrede-Bohin,Philippe Bernard,François Tron,Michael Hertl,Philippe Musette +20 more
TL;DR: A single cycle of rituximab is an effective treatment for pemphigus and its use should be limited to the most severe types of the disease.
Journal ArticleDOI
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Pascal Joly,Maud Maho-Vaillant,Catherine Prost-Squarcioni,Vivien Hébert,Estelle Houivet,Sébastien Calbo,Frédérique Caillot,Marie-Laure Golinski,Bruno Labeille,Catherine Picard-Dahan,Carle Paul,Marie-Aleth Richard,Jean-David Bouaziz,Sophie Duvert-Lehembre,Philippe Bernard,Frédéric Caux,Marina Alexandre,Saskia Ingen-Housz-Oro,Pierre Vabres,Emmanuel Delaporte,Gaëlle Quéreux,Alain Dupuy,Sébastien Debarbieux,Martine Avenel-Audran,Michel D'Incan,Christophe Bedane,Nathalie Beneton,Denis Jullien,Nicolas Dupin,Laurent Misery,Laurent Machet,Marie Beylot-Barry,Olivier Dereure,Bruno Sassolas,Thomas Vermeulin,Jacques Benichou,P. Musette +36 more
TL;DR: Data from this trial suggest that first-line use of rituximab plus short-termprednisone for patients with pemphigus is more effective than using prednisone alone, with fewer adverse events.
Journal ArticleDOI
Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Case–Control Study
Sylvie Bastuji-Garin,Pascal Joly,Pauline Lemordant,Agnès Sparsa,Christophe Bedane,Emmanuel Delaporte,Jean-Claude Roujeau,Philippe Bernard,Jean-Claude Guillaume,Saskia Ingen-Housz-Oro,Hervé Maillard,Catherine Pauwels,Catherine Picard-Dahan,Yes Dutronc,Marie-Aleth Richard +14 more
TL;DR: Risk factors for BP include neurological disorders, particularly dementia and Parkinson's disease, psychiatric disorders (unipolar and bipolar disorders), bedridden condition, and chronic use of several drugs.